How much of a good thing? What duration for interferon Alfa-2b adjuvant therapy?

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3773-3776

  Tarhini, Ahmad A ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALPHA2B INTERFERON; B RAF KINASE INHIBITOR; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN 3; PEGINTERFERON ALPHA2B; QS 21; STAT PROTEIN; TICILIMUMAB;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISTANT METASTASIS FREE SURVIVAL; DRUG APPROVAL; DRUG MEGADOSE; EDITORIAL; HUMAN; MELANOMA; META ANALYSIS (TOPIC); METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; T LYMPHOCYTE; VACCINATION;

HUMANS; INTERFERON-ALPHA; MELANOMA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS;

EID: 84869210903     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.9975     Document Type: Editorial

References (26)

1. Tarhini AA, Kirkwood JM: Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci 1182:47-57, 2009
2. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996 (Pubitemid 26019991)
3. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000 (Pubitemid 30415832)
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001 (Pubitemid 32391207)
5. Kirkwood JM, Manola J, Ibrahim J, et al: A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10:1670-1677, 2004 (Pubitemid 38435557)
6. Wheatley K, Ives N, Hancock B, et al: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241-252, 2003 (Pubitemid 37069655)
7. Wheatley K, Ives N, Eggermont A, et al: Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials. J Clin Oncol 25:478s, 2007 (suppl 18, abstr 8526)
8. Mocellin S, Pasquali S, Rossi CR, et al: Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst 102:493-501, 2010
9. Eggermont AMM, Suciu S, Testori A, et al: Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 30:3810-3818, 2012
10. Eggermont AM, Suciu S, Santinami M, et al: EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. J Clin Oncol 25:473s, 2007 (suppl 18; abstr 8504)
11. Eggermont AM, Suciu S, MacKie R, et al: Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): Randomised controlled trial. Lancet 366:1189-1196, 2005 (Pubitemid 41393597)
12. Grob JJ, Dreno B, de la Salmonière P, et al: Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases - French Cooperative Group on Melanoma. Lancet 351:1905-1910, 1998 (Pubitemid 28297445)
13. Eggermont AM, Suciu S, Santinami M, et al: Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: Final results of EORTC 18991, a randomised phase III trial. Lancet 372:117-126, 2008 (Pubitemid 351952257)
14. Eggermont AM, Suciu S, Testori A, et al: Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 48:218-225, 2012
15. ClinicalTrials.Gov: Adjuvant PEG intron in ulcerated melanoma. http://clinicaltrials.gov/ct/show/NCT01502696
16. Meyer S, Wild PJ, Vogt T, et al: Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 19:e251-e257, 2010
17. Tarhini AA, Stuckert J, Lee S, et al: Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup trial ECOG 1694. J Clin Oncol 27:38-44, 2009
18. Gogas H, Kirkwood JM, Falk CS, et al: Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 116:4326-4333, 2010
19. Moschos SJ, Edington HD, Land SR, et al: Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171, 2006 (Pubitemid 46638955)
20. Critchley-Thorne RJ, Yan N, Nacu S, et al: Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 4:e176, 2007
21. Simons DL, Lee G, Kirkwood JM, et al: Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9:52, 2011
22. Fuertes MB, Kacha AK, Kline J, et al: Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 208:2005-2016, 2011
23. Kruit WH, Suciu S, Dreno B, et al: Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol 26:498s, 2008 (suppl 15; abstr 9065)
24. Louahed J, Gruselle O, Gaulis S, et al: Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol 26:494s, 2008 (suppl 15; abstr 9045)
25. Tarhini AA, Edington H, Butterfield LH, et al: Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: Immunogenicity and biomarker analysis. J Clin Oncol 29:534s, 2011 (suppl 15; abstr 8536)
26. Tarhini AA, Cherian J, Moschos SJ, et al: Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 30:322-328, 2012